Your browser doesn't support javascript.
loading
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
Barnes, Daniel R; Tyrer, Jonathan P; Dennis, Joe; Leslie, Goska; Bolla, Manjeet K; Lush, Michael; Aeilts, Amber M; Aittomäki, Kristiina; Andrieu, Nadine; Andrulis, Irene L; Anton-Culver, Hoda; Arason, Adalgeir; Arun, Banu K; Balmaña, Judith; Bandera, Elisa V; Barkardottir, Rosa B; Berger, Lieke P V; de Gonzalez, Amy Berrington; Berthet, Pascaline; Bialkowska, Katarzyna; Bjørge, Line; Blanco, Amie M; Blok, Marinus J; Bobolis, Kristie A; Bogdanova, Natalia V; Brenton, James D; Butz, Henriett; Buys, Saundra S; Caligo, Maria A; Campbell, Ian; Castillo, Carmen; Claes, Kathleen B M; Colonna, Sarah V; Cook, Linda S; Daly, Mary B; Dansonka-Mieszkowska, Agnieszka; de la Hoya, Miguel; deFazio, Anna; DePersia, Allison; Ding, Yuan Chun; Domchek, Susan M; Dörk, Thilo; Einbeigi, Zakaria; Engel, Christoph; Evans, D Gareth; Foretova, Lenka; Fortner, Renée T; Fostira, Florentia; Foti, Maria Cristina; Friedman, Eitan.
Afiliação
  • Barnes DR; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Tyrer JP; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Leslie G; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Lush M; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Aeilts AM; Department of Internal Medicine, Division of Human Genetics, The Ohio State University, Columbus, OH, USA.
  • Aittomäki K; Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Andrieu N; Inserm U900, Paris, France.
  • Andrulis IL; Institut Curie, Paris, France.
  • Anton-Culver H; Mines ParisTech, Fontainebleau, France.
  • Arason A; PSL Research University, Paris, France.
  • Arun BK; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Balmaña J; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.
  • Bandera EV; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Barkardottir RB; Department of Pathology, Landspitali - the National University Hospital of Iceland, Reykjavik, Iceland.
  • Berger LPV; BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • de Gonzalez AB; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Berthet P; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Bialkowska K; Department of Medical Oncology, University Hospital of Vall d'Hebron, Barcelona, Spain.
  • Bjørge L; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Blanco AM; Department of Pathology, Landspitali - the National University Hospital of Iceland, Reykjavik, Iceland.
  • Blok MJ; BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Bobolis KA; University Medical Center Groningen, Department of Genetics, University of Groningen, Groningen, The Netherlands.
  • Bogdanova NV; Clinical Cancer Epidemiology, Institute of Cancer Research, London, UK.
  • Brenton JD; Département de Biopathologie, Centre François Baclesse, Caen, France.
  • Butz H; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Buys SS; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.
  • Caligo MA; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Campbell I; Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, CA, USA.
  • Castillo C; Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Claes KBM; City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA.
  • Colonna SV; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Cook LS; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Daly MB; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
  • Dansonka-Mieszkowska A; National Tumour Biology Laboratory, National Institute of Oncology, Budapest, Hungary.
  • de la Hoya M; Department of Oncology Biobank, National Institute of Oncology, Budapest, Hungary.
  • deFazio A; Department of Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.
  • DePersia A; SOD Genetica Molecolare, University Hospital, Pisa, Italy.
  • Ding YC; Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Domchek SM; Hereditary Cancer Program, IDIBELL (Bellvitge Biomedical Research Institute), Catalan Institute of Oncology, Barcelona, Spain.
  • Dörk T; Centre for Medical Genetics, Ghent University, Gent, Belgium.
  • Einbeigi Z; Department of Biomolecular Medicine, University of Ghent, Ghent, Belgium.
  • Engel C; Cancer Research Institute Ghent, Ghent, Belgium.
  • Fortner RT; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.
  • Fostira F; Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, CO, USA.
  • Foti MC; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Friedman E; Department of Pathology and Laboratory Medicine, Institute of Oncology and Maria Sklodowska-Curie Cancer Center, Warsaw, Poland.
medRxiv ; 2024 Mar 04.
Article em En | MEDLINE | ID: mdl-38496424
ABSTRACT

Background:

Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA), UK Biobank (UKBB), and FinnGen to identify novel HGSOC susceptibility loci and develop polygenic scores (PGS).

Methods:

We analyzed >22 million variants for 398,238 women. Associations were assessed separately by consortium and meta-analysed. OCAC and CIMBA data were used to develop PGS which were trained on FinnGen data and validated in UKBB and BioBank Japan.

Results:

Eight novel variants were associated with HGSOC risk. An interesting discovery biologically was finding that TP53 3'-UTR SNP rs78378222 was associated with HGSOC (per T allele relative risk (RR)=1.44, 95%CI1.28-1.62, P=1.76×10-9). The optimal PGS included 64,518 variants and was associated with an odds ratio of 1.46 (95%CI1.37-1.54) per standard deviation in the UKBB validation (AUROC curve=0.61, 95%CI0.59-0.62).

Conclusions:

This study represents the largest GWAS for HGSOC to date. The results highlight that improvements in imputation reference panels and increased sample sizes can identify HGSOC associated variants that previously went undetected, resulting in improved PGS. The use of updated PGS in cancer risk prediction algorithms will then improve personalized risk prediction for HGSOC.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article